143 related articles for article (PubMed ID: 8026157)
1. North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
Jones RN; Hoban DJ
Diagn Microbiol Infect Dis; 1994 Jan; 18(1):49-56. PubMed ID: 8026157
[TBL] [Abstract][Full Text] [Related]
2. Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
Jones RN; Reller LB; Rosati LA; Erwin ME; Sanchez ML
Diagn Microbiol Infect Dis; 1992 Jul; 15(5):425-34. PubMed ID: 1643819
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.
Jones RN; Kehrberg EN; Erwin ME; Anderson SC
Diagn Microbiol Infect Dis; 1994 Aug; 19(4):203-15. PubMed ID: 7851083
[TBL] [Abstract][Full Text] [Related]
4. Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group.
Hoban DJ; Jones RN
Chemotherapy; 1995; 41(1):34-8. PubMed ID: 7875019
[TBL] [Abstract][Full Text] [Related]
5. The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.
Hoban DJ; Jones RN; Harrell LJ; Knudson M; Sewell D
Diagn Microbiol Infect Dis; 1993; 17(2):157-61. PubMed ID: 8243037
[TBL] [Abstract][Full Text] [Related]
6. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of the new fluoroquinolone BMY-40062.
Chin NX; Neu H
Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):620-4. PubMed ID: 2120060
[TBL] [Abstract][Full Text] [Related]
8. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
[TBL] [Abstract][Full Text] [Related]
9. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
Tantisiriwat W; Linasmita P
J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
[TBL] [Abstract][Full Text] [Related]
10. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of amifloxacin (WIN 49,375) compared with those of ciprofloxacin and ofloxacin.
Digranes A
Acta Pathol Microbiol Immunol Scand B; 1987 Feb; 95(1):29-32. PubMed ID: 3105246
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).
Zhanel GG; Hisanaga TL; Laing NM; DeCorby MR; Nichol KA; Palatnik LP; Johnson J; Noreddin A; Harding GK; Nicolle LE; Hoban DJ;
Int J Antimicrob Agents; 2005 Nov; 26(5):380-8. PubMed ID: 16243229
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
16. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan.
Tanaka M; Kumazawa J; Matsumoto T; Kobayashi I
Genitourin Med; 1994 Apr; 70(2):90-3. PubMed ID: 8206482
[TBL] [Abstract][Full Text] [Related]
18. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG
Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.
Machka K; Braveny I
Eur J Clin Microbiol; 1987 Aug; 6(4):482-5. PubMed ID: 3117538
[TBL] [Abstract][Full Text] [Related]
20. [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010].
Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M;
Jpn J Antibiot; 2012 Jun; 65(3):181-206. PubMed ID: 23173294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
